Article

Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3

2025-08-12

Abstract excerpt

<h4>ABSTRACT</h4> Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint receptor that plays a central role in T cell exhaustion and immune evasion in cancer. While monoclonal antibodies targeting LAG-3 have entered clinical development, small molecule approaches remain largely unexplored. Here, we report the design and validation of the first-in-class PROTACs for targeted degradation of LAG-3. I...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 346c619e-ce86-5d40-ae9a-5879b200b056
DOI: 10.1101/2025.08.09.669498

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3DOI 10.1101/2025.08.09.669498Read

Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 ProteinSemantic proximity Read

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3Semantic proximity Read

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)Semantic proximity Read

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity Read

Understanding LAG-3 SignalingSemantic proximity Read

Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity Read

The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic ImplicationsSemantic proximity Read

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexitySemantic proximity Read

PD-1/LAG-3 Dysfunctionality Signatures in Human CancersSemantic proximity Read

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With NivolumabSemantic proximity Read